Natural Products as Leads: Anticancer agents (Paclitaxel, Etoposide) MCQs With Answer

Introduction: Natural Products as Leads: Anticancer agents (Paclitaxel, Etoposide) MCQs With Answer provides M.Pharm students a focused, exam-oriented review of two clinically vital natural-product-derived anticancer drugs. This set covers biosources, key structural features, structure–activity relationships, mechanisms of action, pharmacokinetics, formulations, resistance mechanisms, clinical uses, and important adverse effects. Questions are designed to probe deeper understanding—linking chemical structure to biological function and therapeutic challenges—rather than rote facts. The MCQs will help reinforce core concepts from MPC 104T and prepare students for assessments by emphasizing critical thinking and clinically relevant details.

Q1. Which natural source is the primary original source of paclitaxel?

• Bark of Taxus brevifolia
• Leaves of Camptotheca acuminata
• Root of Podophyllum peltatum
• Fruits of Cinchona officinalis

Correct Answer: Bark of Taxus brevifolia

Q2. What is the principal molecular mechanism by which paclitaxel exerts its anticancer effect?

• Inhibition of topoisomerase II leading to double-strand DNA breaks
• Microtubule stabilization leading to mitotic arrest
• Alkylation of DNA causing cross-links
• Intercalation into DNA preventing replication

Correct Answer: Microtubule stabilization leading to mitotic arrest

Q3. Which structural feature of paclitaxel is essential for its antitumor activity?

• The C13 side chain containing the N-benzoyl phenylisoserine moiety
• The quinoline ring fused to the taxane core
• The lactone at C9–C10
• A primary amine at C2 position

Correct Answer: The C13 side chain containing the N-benzoyl phenylisoserine moiety

Q4. Etoposide is a semisynthetic derivative of which naturally occurring compound?

• Podophyllotoxin
• Camptothecin
• Vinblastine
• Taxol

Correct Answer: Podophyllotoxin

Q5. The anticancer action of etoposide primarily involves which molecular target?

• Microtubule assembly inhibitors
• Topoisomerase I poison
• Topoisomerase II poison that stabilizes cleavage complexes
• Thymidylate synthase inhibitor

Correct Answer: Topoisomerase II poison that stabilizes cleavage complexes

Q6. Which adverse effect is classically dose-limiting for paclitaxel therapy?

• Cardiotoxicity (dilated cardiomyopathy)
• Peripheral sensory neuropathy
• Severe hemorrhagic cystitis
• Interstitial pulmonary fibrosis

Correct Answer: Peripheral sensory neuropathy

Q7. Cremophor EL is used in the conventional formulation of paclitaxel. What clinical issue is most associated with Cremophor EL?

• Severe hepatotoxicity due to solvent accumulation
• Hypersensitivity reactions and need for premedication
• Renal tubular necrosis
• Excessive myelosuppression compared with solvent-free forms

Correct Answer: Hypersensitivity reactions and need for premedication

Q8. Which modification converts podophyllotoxin into etoposide with reduced tubulin binding and increased topoisomerase II inhibition?

• Introduction of a glycosidic linkage and removal of C4 hydroxyl
• Methylation of all phenolic OH groups
• Oxidation of the lactone ring to carboxylic acid
• Halogenation at the C7 position

Correct Answer: Introduction of a glycosidic linkage and removal of C4 hydroxyl

Q9. Which pharmacokinetic property is most relevant to dosing adjustments for paclitaxel in hepatic impairment?

• Paclitaxel is primarily renally excreted unchanged
• Hepatic metabolism by CYP2C9 only
• Extensive hepatic metabolism by CYP2C8 and CYP3A4
• High oral bioavailability requiring dose reduction

Correct Answer: Extensive hepatic metabolism by CYP2C8 and CYP3A4

Q10. Which mechanism commonly contributes to resistance to both paclitaxel and etoposide?

• Loss of topoisomerase I expression
• Upregulation of P-glycoprotein (MDR1) efflux pump
• Increased glutathione S-transferase activity only for paclitaxel
• Mutation in thymidylate synthase enzyme

Correct Answer: Upregulation of P-glycoprotein (MDR1) efflux pump

Q11. Which clinical indication is a standard use of paclitaxel?

• Chronic myeloid leukemia as monotherapy
• Advanced ovarian cancer and metastatic breast cancer
• Indolent non-Hodgkin lymphoma exclusively
• First-line therapy for small cell lung carcinoma only

Correct Answer: Advanced ovarian cancer and metastatic breast cancer

Q12. Etoposide phosphate has been developed primarily to address which formulation issue?

• Increase oral bioavailability compared with etoposide
• Provide a water-soluble prodrug to avoid organic solvents for IV use
• Reduce topoisomerase II poisoning to minimize myelosuppression
• Target delivery across the blood–brain barrier

Correct Answer: Provide a water-soluble prodrug to avoid organic solvents for IV use

Q13. At the cellular level, paclitaxel-induced stabilization of microtubules most directly leads to arrest in which phase of the cell cycle?

• G1 phase
• S phase
• M phase (mitosis)
• G2 phase exclusively

Correct Answer: M phase (mitosis)

Q14. Which metabolic pathway is most important for etoposide clearance and relevant to drug–drug interactions?

• Glucuronidation by UGT1A1 only
• Oxidative metabolism by CYP3A4 and conjugation
• Primary renal excretion unchanged with no metabolism
• D-beta oxidation in mitochondria

Correct Answer: Oxidative metabolism by CYP3A4 and conjugation

Q15. Which clinical toxicity profile distinguishes etoposide from many other cytotoxic agents?

• Frequent cardiomyopathy and congestive heart failure
• Risk of therapy-related acute myeloid leukemia (t-AML) associated with topoisomerase II inhibitors
• Severe mucormycosis as a direct drug effect
• Irreversible pulmonary fibrosis in most patients

Correct Answer: Risk of therapy-related acute myeloid leukemia (t-AML) associated with topoisomerase II inhibitors

Q16. Which statement best describes the binding site of paclitaxel on tubulin?

• Paclitaxel binds to alpha-tubulin at the GTP-binding site
• Paclitaxel binds to a distinct site on beta-tubulin within assembled microtubules promoting polymer stabilization
• Paclitaxel intercalates between tubulin dimers preventing polymerization
• Paclitaxel covalently modifies tubulin lysine residues

Correct Answer: Paclitaxel binds to a distinct site on beta-tubulin within assembled microtubules promoting polymer stabilization

Q17. Which structural change in podophyllotoxin analogs is associated with increased topoisomerase II poisoning activity in etoposide?

• Retention of the trans-lactone and removal of the C4 hydroxyl resulting in 4-demethylepipodophyllotoxin glycoside
• Conversion to a saturated cyclohexane core
• Introduction of an aromatic nitro group at C2
• Complete cleavage of the dibenzylbutyrolactone skeleton

Correct Answer: Retention of the trans-lactone and removal of the C4 hydroxyl resulting in 4-demethylepipodophyllotoxin glycoside

Q18. Which formulation innovation reduces paclitaxel-associated hypersensitivity and solvent-related toxicities?

• Higher concentration Cremophor EL formulation
• Albumin-bound nanoparticle paclitaxel (nab-paclitaxel)
• Oral tablet of paclitaxel without excipients
• Co-formulation with etoposide in a single solvent

Correct Answer: Albumin-bound nanoparticle paclitaxel (nab-paclitaxel)

Q19. Which laboratory finding is most commonly observed as a dose-limiting toxicity during etoposide therapy?

• Severe hyperkalemia due to tumor lysis
• Myelosuppression manifesting as neutropenia
• Marked elevation of pancreatic enzymes
• Profound hyponatremia resistant to replacement

Correct Answer: Myelosuppression manifesting as neutropenia

Q20. In structure–activity relationship studies of taxanes, which modification typically reduces activity substantially?

• Removal or alteration of the C13 side chain
• Hydroxylation at non-chiral peripheral sites
• Minor ring flips in non-essential peripheral rings
• Introduction of a polar ester at C7 that is rapidly hydrolyzed

Correct Answer: Removal or alteration of the C13 side chain

Download